Where can I buy shares of Seel?
Real time Seelos Therapeutics Inc (SEEL) stock price quote, stock graph, news & analysis.
Do analysts agree on Seelos Therapeutics (Seel) stock's price targets?
Apr 16, 2022 · Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SEEL shares have decreased by 25.7% and is now trading at $0.5797. View which stocks have been most impacted by COVID-19.
What does Seelos Therapeutics do?
MarketWatch: Stock Market News - Financial News - MarketWatch
Is Seelos Therapeutics a buy right now?
4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currentl...
How has Seelos Therapeutics' stock price been impacted by Coronavirus (COVID-19)?
Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Heal...
What price target have analysts set for SEEL?
4 equities research analysts have issued 12 month target prices for Seelos Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On ave...
Who are Seelos Therapeutics' key executives?
Seelos Therapeutics' management team includes the following people: Raj Mehra , Chairman, President & Chief Executive Officer Jessica Kardish ,...
Who are some of Seelos Therapeutics' key competitors?
Some companies that are related to Seelos Therapeutics include DiaMedica Therapeutics (DMCAF) , Radius Health (RDUS) , Omeros (OMER) , Aadi Bio...
What other stocks do shareholders of Seelos Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VB...
What is Seelos Therapeutics' stock symbol?
Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."
Who are Seelos Therapeutics' major shareholders?
Seelos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.41%),...
Which institutional investors are selling Seelos Therapeutics stock?
SEEL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Woodline Partners LP, Geode C...
About Seelos Therapeutics
Headlines
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders.
Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions
Could The Seelos Therapeutics, Inc. (NASDAQ:SEEL) Ownership Structure Tell Us Something Useful?
Seelos Therapeutics, Inc. (SEEL) Company Bio
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock.
Psychedelic Stock Gainers And Losers From January 20, 2022
Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.
Seelos Therapeutics (SEEL)
GAINERS: Small Pharma (OTC: DMTTF ) shares closed up 14.55% at $0.21 GH Research (NASDAQ: GHRS ) shares closed up 3.35% at $16.99 Field Trip Health (NASDAQ: FTRP ) shares closed up 2.00% at $2.04 LOSERS: Mindset Pharma (OTC: MSSTF ) shares closed down -4.33% at $0.57 Seelos Therapeutics (NASDAQ: SEEL ) shares closed down Full story available on Benzinga.com.
Seelos Therapeutics, Inc. - Sell
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Style Scorecard
Zacks' proprietary data indicates that Seelos Therapeutics, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the SEEL shares relative to the market in the next few months. In addition, Seelos Therapeutics, Inc.
Chart for SEEL
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
Seelos Therapeutics (NASDAQ:SEEL) Price Target and Consensus Rating
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage.
Analyst Price Target Consensus
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Analyst Ratings By Month
Sign-up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter.
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Seelos Therapeutics (NASDAQ:SEEL) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.
Signals & Forecast
According to the issued ratings of 5 analysts in the last year, the consensus rating for Seelos Therapeutics stock is Buy based on the current 5 buy ratings for SEEL. The average twelve-month price target for Seelos Therapeutics is $9.20 with a high price target of $14.00 and a low price target of $6.00. Learn more on SEEL's analyst rating history
Support, Risk & Stop-loss
There are mixed signals in the stock today. The Seelos Therapeutics Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Seelos Therapeutics Inc. stock A Buy?
Seelos Therapeutics Inc. finds support from accumulated volume at $1.09 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Seelos Therapeutics Inc
Seelos Therapeutics Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 13.96 million shares bought and 872.78 thousand shares sold. The last trade was done 46 days ago by Golembiewski Michael Joseph who bough 500 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
